Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Infusion-related reactions to rituximab: frequency, mechanisms and predictors
F Paul, G Cartron - Expert review of clinical immunology, 2019 - Taylor & Francis
Introduction: Rituximab, an anti-CD20 monoclonal antibody (mAb), is indicated in the
treatment of B-cell non-Hodgkin lymphomas, chronic lymphoid leukemia, and rheumatoid …
treatment of B-cell non-Hodgkin lymphomas, chronic lymphoid leukemia, and rheumatoid …
Peripheral B cell subsets in autoimmune diseases: clinical implications and effects of B cell‐targeted therapies
W **, Z Luo, H Yang - Journal of immunology research, 2020 - Wiley Online Library
Antibody‐secreting cells (ASCs) play a fundamental role in humoral immunity. The aberrant
function of ASCs is related to a number of disease states, including autoimmune diseases …
function of ASCs is related to a number of disease states, including autoimmune diseases …
Early effects of first‐line treatment with anti‐interleukin‐6 receptor antibody tocilizumab for chronic active antibody‐mediated rejection in kidney transplantation
A Lavacca, R Presta, C Gai, A Mella… - Clinical …, 2020 - Wiley Online Library
Introduction Chronic active antibody‐mediated rejection (cAMR) is a major determinant of
late allograft failure. Rituximab/immunoglobulins (IVIg)+ plasma exchange (PLEX) showed …
late allograft failure. Rituximab/immunoglobulins (IVIg)+ plasma exchange (PLEX) showed …
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial
M Shipa, LR Santos, DX Nguyen… - The Lancet …, 2023 - thelancet.com
Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease
associated with widespread immune dysregulation and diverse clinical features. Immune …
associated with widespread immune dysregulation and diverse clinical features. Immune …
[HTML][HTML] Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials—Whole blood cytokine release assays are poorly predictive for …
S Vessillier, D Eastwood, B Fox, J Sathish… - Journal of …, 2015 - Elsevier
The therapeutic monoclonal antibody (mAb) TGN1412 (anti-CD28 superagonist) caused
near-fatal cytokine release syndrome (CRS) in all six volunteers during a phase-I clinical …
near-fatal cytokine release syndrome (CRS) in all six volunteers during a phase-I clinical …
Prognosticating outcomes in interstitial lung disease by mediastinal lymph node assessment. An observational cohort study with independent validation
Rationale: Mediastinal lymph node (MLN) enlargement on chest computed tomography (CT)
is prevalent in patients with interstitial lung disease (ILD) and may reflect immunologic …
is prevalent in patients with interstitial lung disease (ILD) and may reflect immunologic …
[HTML][HTML] Differential effects of MS therapeutics on B cells—implications for their use and failure in AQP4-positive NMOSD patients
J Traub, S Häusser-Kinzel, MS Weber - International Journal of Molecular …, 2020 - mdpi.com
B cells are considered major contributors to multiple sclerosis (MS) pathophysiology. While
lately approved disease-modifying drugs like ocrelizumab deplete B cells directly, most MS …
lately approved disease-modifying drugs like ocrelizumab deplete B cells directly, most MS …
[HTML][HTML] Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder
SH Kim, JW Hyun, HJ Kim - Neurochemistry International, 2019 - Elsevier
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of
the central nervous system characterized by severe attacks of optic neuritis (ON) …
the central nervous system characterized by severe attacks of optic neuritis (ON) …
Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B …
W Zhong, X Xu, Z Zhu, L Yang… - International …, 2018 - spandidos-publications.com
Rituximab resistance has become increasingly common in patients with diffuse large B cell
lymphoma (DLBCL). However, the mechanisms involved remain unclear. In this study, we …
lymphoma (DLBCL). However, the mechanisms involved remain unclear. In this study, we …
[HTML][HTML] Anti-CD20 therapy alters the protein signature in experimental murine AIH, but not exclusively towards regeneration
LE Buitrago-Molina, J Dywicki, F Noyan… - Cells, 2021 - mdpi.com
Background: Autoimmune hepatitis (AIH) is a chronic autoimmune inflammatory disease that
usually requires lifelong immunosuppression. Frequent recurrences after the discontinuation …
usually requires lifelong immunosuppression. Frequent recurrences after the discontinuation …